静脉溶栓治疗急性心肌梗死临床疗效观察  

The Effects and Risks of Thrombolytic Therapy in Acute Myocardial Infarction

作　　者：温淑珍[1] 栾树理[1] 

机构地区：[1]青岛市海慈医疗集团海慈医院,266033

出　　处：《青岛医药卫生》2002年第3期7-8,共2页Qingdao Medical Journal

摘　　要：目的 观察急性心肌梗死溶栓治疗的有效性与安全性。方法 符合溶栓治疗条件的急性心肌梗死者100例,随机分为溶栓治疗组和常规治疗对照组,分别为51例和49例。治疗组采用尿激酶150万 U静脉滴注,30min滴完,同时给与肝素抗凝治疗。结果 梗死相关动脉的再通率溶栓治疗组为68.6％,显著高于对照组的12.2％;4周病死率治疗组为7.8％,显著低于对照组的28.6％。结论 对适宜的急性心肌梗死患者溶栓治疗是安全有效的。Objective To observe the efficacy and safety of thrombolytic therapy on patients with a-cute myocardial infarction. Methods There were 100 cases to be divided into two groups:urokinase group and routine therapy group. In urokinase group, the patients were treated with intravenous urokinase 1500000 IU over 30 minutes. Results The reperfusion rate in the infarct-related artery (IRA) was significantly higher in urokinase group than in control group (68.6% vs 12. 2%). The mortality during 4 weeks was significantly lower in urokinase group than in control group(7.8% vs 28.6%).Conclusion In the absence of contraindication,administration of intravenous urokinase to patients with acute myocardial infarction is effective and safe.

关 键 词：急性心肌梗死 溶栓治疗 尿激酶 

分 类 号：R542.22[医药卫生—心血管疾病]